Search for the latest oncology news by tumour type
ASCO 2025: Pembrolizumab gives head and neck cancer patients extra years disease-free
An immunotherapy helps patients live years longer without their cancer getting worse or coming back,…
Browsing: Tumour Stream
ASCO 2025: Adding nivolumab to chemoradiotherapy after surgery can decrease chance of recurrence in head and neck cancer
Results from the international phase 3 NIVOPOSTOP clinical trial found that adding nivolumab to chemoradiotherapy…
ASCO 2025: Avelumab cetuximab combo improves PFS for for cutaneous squamous cell carcinoma
In patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma (cSCC),…
ASCO 2025: First phase 2 RCT of CAR T-cell therapy in solid tumours finds promising results
Patients with advanced gastric or gastro-oesophageal junction (GEJ) cancer treated with CAR T-cell therapy lived…
ASCO 2025: Artificial intelligence assistance can help improve accuracy in identifying HER2-low and HER2-ultralow breast cancers, avoid misclassification
Results from a multinational study found that using artificial intelligence (AI) assistance can help pathologists…
ASCO 2025: Trastuzumab deruxtecan can help some people with advanced gastric cancers live about 3 months longer
The international phase 3 DESTINY-Gastric04 clinical trial found that second-line treatment with trastuzumab deruxtecan can help…
Global warming may raise women’s cancer risk
Scientists investigating the impact of climate change on women’s health have found that increased heat…
ASCO 2025: Adding niraparib to standard treatment may slow cancer growth for some patients with mCSPC
Results from the international phase 3 AMPLTUDE clinical trial found that adding niraparib to abiraterone…
ESMO Breast 2025: Immunotherapy research shows promising results for patients with advanced HER2-positive breast cancer
Results from the DIAmOND clinical trial have shown that adding dual immunotherapy to existing treatments…
ASCO 2025: Addition of lurbinectedin to first-line maintenance treatment for small cell lung cancer prolongs survival, according to phase 3 trial
Small cell lung cancer (SCLC) accounts for approximately 15% of lung cancers, and most patients…